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ORIGINAL ARTICLE
Disrupted iron regulation in the brain and periphery in cocaine
addiction
KD Ersche1,2, J Acosta-Cabronero3, PS Jones4, H Ziauddeen1,2,5, RPL van Swelm6,7, CMM Laarakkers6,7, R Raha-Chowdhury4 and
GB Williams4
Stimulant drugs acutely increase dopamine neurotransmission in the brain, and chronic use leads to neuroadaptive changes in
the mesolimbic dopamine system and morphological changes in basal ganglia structures. Little is known about the mechanisms
underlying these changes but preclinical evidence suggests that iron, a coenzyme in dopamine synthesis and storage, may be
a candidate mediator. Iron is present in high concentrations in the basal ganglia and stimulant drugs may interfere with iron
homeostasis. We hypothesised that morphological brain changes in cocaine addiction relate to abnormal iron regulation in
the brain and periphery. We determined iron concentration in the brain, using quantitative susceptibility mapping, and in the
periphery, using iron markers in circulating blood, in 44 patients with cocaine addiction and 44 healthy controls. Cocaine-addicted
individuals showed excess iron accumulation in the globus pallidus, which strongly correlated with duration of cocaine use, and
mild iron deﬁciency in the periphery, which was associated with low iron levels in the red nucleus. Our ﬁndings show that iron
dysregulation occurs in cocaine addiction and suggest that it arises consequent to chronic cocaine use. Putamen enlargement in
these individuals was unrelated to iron concentrations, suggesting that these are co-occurring morphological changes that may
respectively reﬂect predisposition to, and consequences of cocaine addiction. Understanding the mechanisms by which cocaine
affects iron metabolism may reveal novel therapeutic targets, and determine the value of iron levels in the brain and periphery as
biomarkers of vulnerability to, as well as progression and response to treatment of cocaine addiction.
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INTRODUCTION
Neuroscientiﬁc research in stimulant drug addiction has greatly
advanced our understanding of the neurobiology of addiction.
Although these advances have not yet translated into more
effective treatments or prevention strategies, they have clearly
demonstrated that addiction is a brain disorder.1 Critical to this
has been accumulating evidence of the association of morpho-
logical brain changes with stimulant drug addiction, the most
robust of these being the enlargement of the putamen, which is
frequently seen in stimulant-addicted individuals.2–8 Preclinical
animal models have shown that this abnormality is caused by
drug effects, as the stimulant-induced decline in dopamine D2
receptors in the ventral striatum is directly linked with the volume
increase in the dorsal striatum (putamen).9 This is thought to
reﬂect a hypothesized ventral-to-dorsal progression in the
behavioural shift from voluntary drug use to compulsive drug-
taking10 and increased putamen volume may thus reﬂect a neural
substrate of the transition to addiction. However, as it has also
been observed in unaffected ﬁrst-degree relatives of stimulant-
addicted individuals5 and in patients with obsessive-compulsive
disorder (OCD),11 putamen enlargement may partly represent a
predisposing factor for compulsive behaviours.
Although these morphological brain changes in addiction
have been well-characterized, the mechanisms by which stimulant
drugs, whose primary pharmacological effect is to increase
dopamine transmission, result in such changes remains unknown.
One potential candidate mediator may be iron, which has a vital
role in a many physiological processes, including in the synthesis
of dopamine by providing energy for dopamine metabolism and
storage.12 Given the pivotal role that iron plays in both health and
disease, its metabolism is very tightly regulated. As an essential
micronutrient, iron must be obtained from the diet and cannot be
excreted (except by blood loss). Iron homeostasis is particularly
critical in the brain because excess iron can result in neuronal
death through the production of reactive oxygen species,13 and
iron deﬁciency will impair dopamine synthesis and monoamine
metabolism.14 Homeostasis is thus carefully controlled through
various, highly complex transport systems and feedback loops.15,16
Disruptions in the regulation of iron may therefore occur at
various levels, resulting in a variety of different pathologies,
prominent among which are neurodegenerative disorders.17,18
Critical to the regulation of iron is the blood–brain barrier,
which decouples iron levels in the periphery from the brain. Iron
enters the brain as diferric transferrin (Tf) via the transferrin
receptors (TfR1) and the divalent metal transporter 1 (DMT1).19
The transmembrane protein ferroportin 1 transports iron from the
luminal to the abluminal side of a cell,16,20 where it is stored as a
ferritin, mainly in the oligodendrocytes but also in microglia and
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astrocytes.21 As the brain is one of the most metabolically active
organs in the body, its demand for iron generally exceeds the rate
of transferrin uptake, which means that the shortfall has to be
covered from internal storage.22 To ensure that the internal
storage is able to meet the demand, even in the event of
inﬂammation or hypoxia, iron transport in brain parenchyma is
regulated by the peptide hepcidin.20,23 The regional distribution of
iron in the brain is, however, not equal. Dopamine-rich brain
regions like the basal ganglia are particularly susceptible to iron
deposition, but the factors determining the regional distribution
of iron remain elusive.12
Several lines of evidence suggest a dysregulation of iron
homeostasis in stimulant drug addiction. First, regular use of
stimulant drugs increases the permeability of the blood–brain
barrier, allowing more iron to enter the brain parenchyma.13,24
Second, in animal models stimulant exposure has been shown to
be associated with iron deposition in the basal ganglia mainly in
oligodendrocytes.25 Third, stimulant drugs impair innate
immunity,26 rendering chronic stimulant users vulnerable to
infection and chronic inﬂammation,27 disrupting peripheral iron
homeostasis by reducing iron absorption or heam synthesis, and
this is reﬂected by reduced serum iron and transferrin saturation.28
Finally, chronic stimulant drug use may change dietary prefer-
ences, particularly towards fatty foods,29–31 thereby affecting iron
absorption due to lack of iron transporter and bioavailability.
We hypothesised that cocaine addiction is associated with
disruptions in iron regulation, as reﬂected by increased iron
concentration in the brain and reduced iron levels in the blood.
We therefore sought to determine iron concentration in the brain,
using quantitative susceptibility mapping,32 and in the periphery,
using markers in circulating blood, in patients with cocaine
addiction and age-matched healthy control volunteers. We
predicted that increased levels of brain iron would be associated
with the duration of cocaine use and basal ganglia volume in the
cocaine-addicted patients.
MATERIALS AND METHODS
Study sample and procedures
We recruited 44 individuals (95% male) with a chronic history of cocaine
use, meeting the DSM-IV-TR criteria for cocaine dependence, and 44
matched healthy control volunteers (93% male) without a history of drug
or alcohol dependence. The diagnosis of cocaine dependence was
ascertained using the Structured Clinical Interview for DSM-IV, and these
individuals are subsequently referred to as cocaine use disorder (CUD).
None of the control participants had ever met DSM-IV-TR criteria for
substance dependence; for further details see Supplementary Material. All
participants provided written informed consent before they underwent a
medical review and psychiatric screening. Exclusion criteria included major
medical or neurological illness, lifetime history of a psychotic disorder,
history of a traumatic head injury, or any contra-indications to MR-
scanning. Dietary iron intake was calculated from the Food Frequency
Questionnaire (http://www.srl.cam.ac.uk/epic/nutmethod/FFQ.shtml). Diet-
related variations in iron absorption were estimated using the algorithms
developed by Hallberg and Hulthen.33 All participants provided blood
samples for the analysis of iron proteins in serum (that is, ferritin, iron,
transferrin), hepcidin-25, acute inﬂammation (that is, C-reactive protein
(CRP)) and haematological status. This study was approved by the National
Research Ethics Committee (12/EE/0519; PI: KDE).
Neuroimaging data acquisition
All participants underwent magnetic resonance brain scans at the Wolfson
Brain Imaging Centre, University of Cambridge (UK) using a 3T Siemens
Magnetom Tim-Trio scanner. T1-weighted images (MPRAGE) and
susceptibility-weighted images (SWI) were acquired for all participants.
Brain scans were screened for normal radiological appearance by
neuroradiologists. Scanning data from one control participant and three
CUD patients were removed due to poor quality, leaving a total of 84
participants (43 controls, 41 CUD). Detailed neuroimaging methods are
provided in the Supplementary Material.
Statistical analysis
Data were analysed using a ﬁve-step strategy, as outlined below, and
described fully in Supplementary Material. All statistical tests were two-
tailed. In light of the multiple statistical tests, we applied a more stringent
P-value, by dividing the initial P-threshold (0.05) by 10, resulting in a
threshold of Po0.005. However, as this was an exploratory analysis, results
reaching the Po0.05 threshold are also reported, though not referred to
as signiﬁcant in the discussion.
1. Demographics, clinical data and peripheral iron markers were examined
in SPSS (v21) using independent-sample t-tests or Mann–Whitney
U-tests. Chi-square or Fisher’s exact tests were used for categorical data.
2. At whole brain level, gray matter volume comparisons were conducted
on the MPRAGE images using FSL-VBM and CamBA for permutation
testing. Quantitative susceptibility maps (QSM), a validated measure of
brain iron concentration,32 were reconstructed from SWI data.34 Brieﬂy,
multi-channel complex data were combined using a modiﬁed adaptive
algorithm.35 The combined phase images were unwrapped with a
continuous Laplacian approach,36 and the local ﬁeld was revealed
through global extraction of the background ﬁeld with spherical mean
value ﬁltering.37 QSM was estimated with the morphology-enabled,
non-linear dipole inversion method,38 and the maps were warped into a
study-wise space with a previously described processing stream34 using
ANTs (v2.1). Finally, FSL Randomize (v2.9) was used for QSM statistical
analysis (Figure 1).
3. Regions-of-interest (ROIs) were deﬁned for nine iron-rich structures,
which were manually traced on the QSM group template (Figure 2). In
addition, to directly compare QSM in the putamen and globus pallidus
(GP) against gray matter probabilities in the putamen, we applied an
automated, reproducible algorithm for subcortical segmentation to the
MPRAGE template using FSL-FIRST (Figures 3 and 4). Mean and median
values for each ROI were imported into SPSS for group comparison and
correlational analyses.
4. Correlational analyses were performed separately in each group to
examine the relationships between iron concentration in both brain and
periphery, with brain structure, age and duration of cocaine use.
5. Predictors of iron concentration in the GP were examined using a
multiple regression model in SPSS with DSM-IV drug dependency
status, smoking status, serum ferritin and transferrin saturation included
as predictor variables.
RESULTS
Demographics and peripheral iron markers
The two groups were matched in terms of age, gender,
handedness, body mass, and alcohol consumption (Table 1). The
groups did not differ on vital signs, indicating that CUD patients
were not acutely intoxicated.
The estimated iron absorption calculated from dietary iron
intake did not differ between CUD and controls (t81 =− 0.02,
P= 0.988). CUD patients had signiﬁcantly lower serum iron levels
than controls and signiﬁcantly higher levels of the acute-phase
reactants CRP and ferritin, indicative of inﬂammation (Table 1).
Levels of transferrin (iron transporter) and hepcidin (iron
regulatory protein) did not differ between the groups but CUD
patients had signiﬁcantly lower transferrin saturation, suggesting
iron deﬁciency. Ferritin concentration was correlated with
hepcidin levels in controls (r= 0.40, P= 0.008) and less strongly
in CUD (r= 0.38, P= 0.016), suggesting that in patients the increase
in ferritin may also be related to inﬂammation and other factors.
The haematological proﬁle in CUD patients further indicates mild
iron deﬁciency with a microcytic blood picture (Table 1).
Gray matter volume and brain iron concentration
Compared with the control group, gray matter volume at whole
brain level was signiﬁcantly increased in CUD in the putamen and
the cerebellum, and signiﬁcantly reduced in the insula, orbito-
frontal, medial frontal, anterior cingulate and temporoparietal
cortices (Figure 1a). Similarly, comparison of voxel-wise iron
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concentration (as indexed by QSM) at whole brain level, are shown
in Figure 1b.
The ROI analysis showed signiﬁcantly higher QSM concentration
in CUD patients compared with controls in both segments of the
GP (internal (GPi): t82 =− 2.88, P= 0.005 and external (GPe):
t82 =− 4.05, Po0.001). CUD patients also had reduced QSM in
the red nucleus (t82 =− 2.14, P= 0.036; Figure 2a), but this ﬁnding
did not survive the more stringent threshold of Po0.005, which
we applied due to multiple statistical testing (see also
Supplementary Table S1).
To evaluate whether the increased putamen volume in CUD
patients was associated with iron concentration in this region,
correlations between gray matter volume and QSM were examined
separately in both groups using (Figure 4, Supplementary Table
S2). As putamen volume is expected to decrease with age (in
contrast to QSM, which increases with age),39 age effects were
also examined. In controls, putamen gray matter volume was
signiﬁcantly negatively correlated with QSM (r=− 0.53, Po0.001)
and age (r=− 0.37, P= 0.015) but these relationships were not
seen in CUD (QSM: r=− 0.13, P= 0.416; age: r= 0.05, P= 0.770). In
both groups, putamen volume was also unrelated to QSM in the
GP, and was not associated with the duration of cocaine use
(r= 0.19, P= 0.229).
There were no group differences with respect to GP or caudate
volume, and no signiﬁcant volume — QSM relationships in the GP
(Supplementary Material).
Brain iron accumulation as a function of age and cocaine use
Consistent with prior work in healthy ageing,34,40 in controls iron
concentration was correlated with age in the putamen (r= 0.67,
Po0.001), red nucleus (r= 0.64, Po0.001), substantia inominata
(r= 0.49, P= 0.001), substantia nigra (r= 0.48, P = 0.001), motor
cortex (r= 0.43, P= 0.005), and caudate nucleus (r= 0.39, P= 0.010).
However, in CUD patients, these correlations were only seen in the
motor cortex (r= 0.44, P= 0.005) and substantia nigra (r= 0.43,
P= 0.005), suggesting that the pattern of iron accumulation with
normal ageing is altered in cocaine addiction.
As shown in Figure 2b, the duration of cocaine use correlated
strongly with QSM in the GPe (r= 0.49, P= 0.001), the substantia
nigra (r= 0.34, P= 0.028) and dentate nucleus (r= 0.33, P= 0.034),
but not in the GPi (r= 0.28, P= 0.069). QSM in the red nucleus was
signiﬁcantly correlated with low transferrin saturation in CUD
patients (r= 0.54, Po0.001, Figure 2c) but not in controls (r= -0.08,
P= 0.628). Only in the dentate nucleus was QSM correlated with
transferrin saturation in both groups (CUD: r= 0.43, P= 0.005,
controls: r= 0.31, P= 0.045). For further details, see Supplementary
Material.
Predictors of iron accumulation in the GP
Multiple regression revealed that a third of the variance (34%) of
QSM in the GPe was explained by drug dependency (R2 = 0.34;
F7,74 = 5.1832, Po0.001), with cocaine dependence (β= 0.57,
P= 0.036) and the absence of opiate dependence (β=− 0.47,
P= 0.001) being the strongest predictors in the model. For the GPi,
the same model explained only 18% of the variance of QSM
(R2 = 0.18; F7,74 = 2.27, P= 0.038) with the absence of opiate
dependence being the only signiﬁcant predictor (β=− 0.37,
P= 0.018); see Supplementary Material for details.
Given the strong negative relationship with opiate dependence,
the CUD group was divided post hoc into two subgroups with and
without comorbid opiate dependence (CUD+O, n= 27; CUD−O,
n= 14). There were no signiﬁcant demographic differences
between the CUD-subgroups. As shown in Figure 3b, one-way
ANOVA revealed signiﬁcant group differences in QSM in GPe
(F2,81 = 13.21, Po0.001) such that QSM was increased in both
CUD-subgroups compared with controls (both Tukey’s Po0.05)
and signiﬁcantly increased in CUD−O compared with CUD+O
(P= 0.013). As shown in Figures 3d and e, the duration of cocaine
use was signiﬁcantly correlated with QSM in CUD+O (r= 0.48,
P= 0.017) and in CUD−O (r= 0.54, P= 0.047) (Fisher’s z-score =−
0.34, P= 0.737). The group effect in QSM in the GPi (F2,81 = 6.87,
P= 0.002) was driven by signiﬁcantly higher levels of QSM in
CUD−O compared with controls (P= 0.001). Differences between
CUD+O and controls (P= 0.253) and CUD+O and CUD−O
Figure 1. Whole brain maps of signiﬁcant group differences. (a) Group comparison of modulated gray matter volume at whole brain level.
Voxels colored in blue indicate brain areas in which patients with cocaine use disorder (CUD) have reduced gray matter volume compared
with control volunteers, and voxels colored in red indicate brain areas in which CUD patients have abnormally increased gray matter volume.
The statistical results are overlaid on the FSL MNI152 standard T1-image and the numbers beneath each section of the image refer to its
position (mm) relative to the inter-commissural plane in standard stereotactic space. (b) Group comparison of iron concentration as estimated
by quantitative susceptibility mapping (QSM) at whole brain level. Clusters colored in turquoise indicate greater iron concentration in CUD
patients compared with control volunteers.
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(P= 0.070) were non-signiﬁcant (Figure 3c). No relationships were
found between QSM in GPi and the duration of cocaine use or the
duration of opiate use (Supplementary Material).
DISCUSSION
We demonstrate for, we believe, the ﬁrst time in humans that
chronic cocaine use is associated with excessive iron accumulation
in the brain, which is localised to the GP and correlates strongly
with the duration of regular cocaine use, but is unrelated to GP
volume. We further report a signiﬁcant reduction in serum levels of
transferrin-bound iron (transferrin saturation), which was associated
with low iron concentration in the red nucleus. These ﬁndings
suggest that iron regulation is disrupted in cocaine addiction.
Although we replicated the established ﬁndings of putamen
enlargement in CUD, we did not ﬁnd supporting evidence for this
being related to iron accumulation either in the GP or the putamen,
suggesting that both are separate, co-occurring morphological
changes in cocaine addiction (Supplementary Table S3).
Iron accumulation in the GP: a putative consequence of cocaine
exposure?
Excessive brain iron accumulation is a recognised pathological
change in neurodegenerative diseases and conditions caused by
inherited abnormalities of iron metabolism, but not one that has
been described previously in cocaine addiction. Indeed, the
highly localized iron accumulation in the GP in CUD patients is
reminiscent of the ‘eye of the tiger’ sign on T2-weighted magnetic
resonance imaging in pantothenate kinase-associated neuro-
degeneration (formerly Hallervorden-Spatz syndrome); a rare,
rapidly progressive neurodegenerative disorder with childhood
onset and prominent extrapyramidal symptoms. This condition is
characterised by disturbances of systemic iron metabolism caused
by mutations in the PANK2 gene.41 It thus demonstrates a clear
link between iron dysregulation, basal ganglia dysfunction and
excessive iron accumulation selectively in the GP, which may be
very relevant to understanding our ﬁnding in CUD, though
the precise mechanisms of how this arises and relates to the
progression of the clinical syndrome remain to be determined.
High concentrations of iron are generally seen in the
oligodendrocytes in dopamine-rich basal ganglia structures, the
highest being in the GABAergic interneurons of the GP. Although
the GP itself is not a dopamine-rich structure, its function within
the basal ganglia network is, however, dependent on dopaminer-
gic inputs.42–44 Unlike other regions such as the putamen, which
accumulate iron slowly but steadily throughout the lifespan, iron
concentration in the GP increases rapidly during the ﬁrst two
decades of life (when iron is essential for growth and myelination),
Figure 2. Regional group differences in iron concentration. (a) Group comparison of iron concentration in an region of interest (ROI)-based
approach of iron-rich brain regions. CUD patients showed a signiﬁcant increase in QSM of 14% in the globus pallidus external (GPe), of 11% in
the globus pallidus internal (GPi), and a marginal increase of 6% in the substantia nigra. CUD patients further showed a signiﬁcant reduction
in QSM of 13% in the red nucleus; however, the 12% reduction in the putamen was non-signiﬁcant (for statistical details see Supplementary
Material). (b) Excessive iron accumulation in the GPe in CUD patients was signiﬁcantly associated with the duration of cocaine use. (c) The
reduction of iron concentration in the red nucleus in CUD patients was associated with a decrease in iron bound to transferrin in circulating
blood. (Error bars denote s.e.m., **P o 0.005 and *P o 0.05). CUD, cocaine use disorder; QSM, quantitative susceptibility maps.
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and then begins to plateau around the age of 30 years.21 GP iron
concentration in our CUD group not only exceeded that of age-
matched healthy volunteers (mean age 40 years), but also
correlated strongly with the duration of cocaine use (Figure 2).
Preclinical work in monkeys has shown a similarly selective
increase in iron concentration in the GP following exposure to
methamphetamine, at a magnitude 2.5 times that in control
animals.25 In humans, bilateral GP infarction is a common
symptom of cocaine overdose.45–47 Taken together, these ﬁndings
suggest that this excess iron accumulation in the GP is a regionally
speciﬁc effect of stimulant drug exposure.
Mechanisms and functional implications of excess iron
accumulation in the GP
Evidence from animal models and human studies revealed that
the stimulant-induced iron increase in the GP occurs with a delay
of up to 18 months after exposure.25 Although iron accumulation
has primary been regarded as a dopamine-driven mechanism,48
this abnormal iron increase in the GP appears to reﬂect
compensatory GABAergic adaptations to excessive stimulant-
induced dopaminergic excitation in the striatum.49,50 However,
the putative involvement of GABA and glutamate in iron
homeostasis50 might also play a role in this process. Though iron
concentrations in CUD patients were signiﬁcantly increased in
both segments of the GP, they were only related to the duration of
cocaine use in the GPe. This cocaine-related iron accumulation
further appeared to be attenuated by comorbid opiate addiction
(Figure 3); a ﬁnding that requires further investigation. Consistent
with previous work,51 the majority of our CUD+O reported using
heroin in particular to alleviate cocaine-induced over-excitability
and to enhance their control over their cocaine use. Whether
these experiences are related to the attenuated iron increase in
the GP remains to be determined.
The GPe and the subthalamic nucleus form the so-called
indirect striatal pathway,52 which has been hypothesized to act as
‘brake’ for inhibiting ongoing behaviour53 and to mediate learning
of aversive outcomes54,55—functions that are substantially
impaired in stimulant-dependent individuals.56,57 Owing to its
‘strategic location’, the GPe has been suggested to exert a
powerful inhibitory control on basal ganglia output structures,58
which are implicated in habit learning and automaticity.59 The
indirect striatocortical pathway is thought to be modulated via
striatal dopamine receptor type 2 function, which has been shown
to decline following repeated stimulant drug exposure9,60 and to
underlie to compulsive drug-taking in addicted individuals.61,62
Intriguingly, selective damage of the GP has repeatedly been
associated with compulsive behaviours unrelated to drug
taking,63–65 it is thus conceivable that GP dysfunction contributes
to disruptions in the balance between goal-directed and habitual
action control that characterises cocaine addiction.10 However,
despite existing histological evidence of the stimulant-induced
increase in the GP25 and preliminary preclinical evidence
suggesting that an imbalance between direct and indirect striatal
pathway activity might mediate the transition to addiction,66 the
underlying mechanisms and functional effects of iron dyregula-
tion on addictive behaviour require further investigation.
Iron dysregulation in the periphery in cocaine addiction
We found evidence of dysregulation of peripheral iron metabolism
in our CUD sample with signiﬁcantly reduced levels of iron and
Figure 3. Cocaine-related abnormalities. (a) Illustration of the globus pallidus (GP), which was our region of interest. (b) Post hoc comparison of
iron concentration in the GPe revealed signiﬁcant differences between the groups, such that QSM levels in CUD patients with comorbid
opiate dependence fell midway between the levels seen in healthy volunteers and CUD patients without comorbid opiate dependence. (c)
Iron concentration in the GPi differed signiﬁcantly between the groups, which was driven by signiﬁcantly increased QSM in CUD patients
without opiate dependence compared with healthy control volunteers. (Error bars denote s.e.m., **P o 0.005 and *P o 0.05). (d, e) In both
CUD subgroups, excessive iron accumulation in the GPe was associated with the duration of cocaine use, supporting the notion that chronic
cocaine use is implicated in the observed pathology. No relationships were observed between iron concentration in the GPi and the duration
of cocaine use or with the duration of opiate use (for statistical details see text and Supplementary Material). CUD, cocaine use disorder; GPe,
external GP; GPi, internal GP; QSM, quantitative susceptibility maps.
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transferrin saturation (Table 1). Given that transferrin is the major
iron transporter protein, one would anticipate increased rather
than decreased transferrin saturation in mild iron deﬁciency.
However, during acute inﬂammation (as reﬂected by increased
CRP levels, and abnormal eosinophil, lymphocyte and neutrophil
counts), ferritin levels may increase disproportionately due to
hepatic ferritin production, while iron release remains propor-
tionate to the cellular ferritin content, resulting in low transferrin
saturation as seen in the present study. The rather modest
increase in ferritin during inﬂammation in CUD patients further
supports the notion of peripheral iron dysregulation.
As iron crosses the blood–brain barrier bound to transferrin,67
the correlation between peripheral transferrin saturation and low
iron levels in the red nucleus in CUD patients also concurs with the
notion of peripheral iron deﬁciency (Figure 2c). In conditions of
iron overload, the exact opposite pattern has been reported,
namely excessive iron accumulation in the red nucleus and
increased transferrin saturation in the periphery.68
A possible mediating role of peripheral inﬂammation in central
iron accumulation?
Given that we see elevated serum CRP and ferritin levels in the
CUD, it may be that inﬂammation is a mediator of the increased
iron brain iron concentration. Although we found no signiﬁcant
correlations between CRP levels and QSM, this does not rule out
this possibility, as QSM cannot separately detect the ferritin L-
isoform, which is associated with inﬂammation. Ferritin has two
dominant isoforms, light polypeptide (L-ferritin) and heavy
polypeptide (H-ferritin). H-ferritin has a critical regulatory role in
iron metabolism, whereas the physically more stable L-ferritin is
more involved in iron storage of iron.69 H-ferritin is involved
myelination and adenosine triphosphate (ATP)70 and predomi-
nates in the young adult brain. However with aging, L-ferritin
levels in the brain increase with the accumulation of myelin debris
and the breakdown of neuromelalin,13 and L-ferritin is thought to
play a critical role in neurodegeneration.69 To examine the
association between iron accumulation in the brain and inﬂam-
mation, it is necessary to speciﬁcally measure L-ferritin, which is
not possible at present with QSM, and this remains an important
area of future research.
Putamen enlargement is unrelated to iron levels
Though we replicated the ﬁnding of putamen enlargement in
chronic stimulant drug users2–8 in our CUD group, we did not ﬁnd
supporting evidence for relationships between volumetric
changes and abnormal iron concentration. Despite the group
differences in putamen volume, iron concentration in the puta-
men did not signiﬁcantly differ between the two groups (Figure 4).
However, unlike the control group, CUD patients showed no
correlation between putamen iron and age. Clearly, the pattern
seen in CUD does not seem to accord with either a normal
ageing39 or a neurodegenerative picture.71 Given that enlarge-
ment of the putamen has also been observed in their unaffected
biological siblings,5 it likely represents a vulnerability factor to,
rather than a consequence of, cocaine addiction.
Strengths and weaknesses
The strengths of the study are its methodology, the simultaneous
examination of central and peripheral iron and the relatively large
sample size. For the measurements of brain iron QSM has proven
Figure 4. Possible pre-existing abnormalities. (a) Illustration of the putamen, which was our region of interest. (b) Group comparisons of gray
matter volume showed a signiﬁcantly increase in CUD patients compared with controls. (c) Levels of QSM were not measurable different
between the groups. (Error bars denote s.e.m., NS indicates P4 0.05 and *P o 0.05). (d) Correlational analysis between gray matter volume
(indexed by the mean of the modulated gray matter segment calculated over the FIRST ROI) and brain iron concentration (as indexed by QSM)
are inversely correlated in control participants (r=− 0.53, P o 0.001). (d) Gray matter volume was unrelated with QSM in CUD (r=− 0.13,
P= 0.416). CUD, cocaine use disorder; QSM, quantitative susceptibility maps; ROI, regions-of-interest.
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superior to R2,40 and has been cross-validated against both other
MR techniques and post-mortem iron measurements.32 Although
QSM primarily indexes iron concentration, it might also capture
other processes such as lower myelin levels,72,73 it remains unclear
to what extent such alterations might have a role in CUD and in the
present results. Limitations include the cross-sectional design, the
lack of behavioural assessments and the absence of measures iron
absorption/transport, such as DMT1 and ferroportin (particularly
iron absorption through gut mucosa), which would help determine
the speciﬁc disruptions in iron regulation in CUD patients.
Implications and outlook
Over the last three decades there has been a major conceptual
shift in our understanding of drug addiction, from simply being a
behavioural problem to a brain disorder.1,74 There have also been
signiﬁcant advances in addressing the basic question of causality,
namely as to whether the observed brain changes in addicted
individuals were causal or consequential to drug addiction.
However, we know surprisingly little about the neurobiological
mechanisms by which stimulant drugs interact with vulnerability
factors leading to the observed neuropathology. In this study, we
provide ﬁrst evidence of a potential mechanism, which seems to
arise consequent to cocaine exposure, namely the dysregulation
of iron metabolism. Future research is warranted to identify the
precise mechanisms by which stimulant drugs interact with
iron regulation, that is, changing the permeability of the
blood-brain-barrier, altering intracellular iron trafﬁcking, or
disrupting cellular iron management. Another possibility that
requires further exploration is the role of peripheral inﬂammation
in CUD, and its contributory or mediating role in iron accumula-
tion in the brain, given the growing evidence of inﬂammatory
conditions affecting iron homeostasis through a process of
translational regulation of ferritin.75
The demonstration of iron dysregulation in cocaine addiction
raises several important questions including, how this develops
over time, whether iron deﬁciency increases the vulnerability to
developing stimulant addiction, contributes to the persistence of
the disorder, or leads to the long-term sequelae such as accelerated
brain ageing and behavioural and motor rigidity that continue in
recovery. These will require longitudinal studies to evaluate the
temporal course and stability of imbalances in iron regulation, and
relate them to other key aspects of the illness. A more critical question
that follows from the above is whether impaired iron regulation
might be a biomarker of disease progression or a therapeutic
target for cocaine addiction, either through addressing peripheral
iron deﬁciency to modify disease course, or by slowing or
reversing the central accumulation of iron. Given that stimulant
addiction remains a signiﬁcant public health problem associated
with considerable harm and morbidity, with few pharmacological
treatments and only modestly successful psychosocial treatments,
elucidating this mechanism may offer the possibility of developing
some much needed new interventions.
Table 1. Demographics, haematological and peripheral iron measures
Demographics Control Group Cocaine Group Group Comparison
Mean (± s.d.) Mean ( ± s.d.) t or U P-value
Gender ratio (male: female) 40: 3 39: 2 Fisher’s 1.000
Handedness (right: left: ambidextrous) 37: 5: 1 34: 6: 1 Fisher’s 0.875
Age (years) 41.7 (±10.6) 40.5 (±7.6) 0.60 0.553
Body mass index 24.8 (±3.1) 23.4 (±4.1) 1.75 0.084
Alcohol consumption (AUDIT score) 3.9 (±1.9) 4.0 (±4.8) 1.24 0.222
Selected markers related to iron status
Dietary iron (mg) 11.6 (±3.7) 13.4 (±6.2) − 1.66 0.100
Serum iron (μmol l− 1) 17.9 (±5.9) 12.8 (±5.5) 4.03 o0.001
Serum ferritin (μg l− 1) 65.0 (±46.1) 103.2 (±75.2) − 2.80 0.008
Serum transferrin (g l− 1) 2.8 (±0.4) 2.6 (±0.4) 1.13 0.332
Transferrin saturation (%) 29.1 (±9.6) 21.9 (±10.3) 3.32 0.001
Serum hepcidin-25 (nM) 3.4 (±3.8) 3.7 (±3.0) 710.5 0.125
Selected inﬂammatory marker
C-reactive protein (mg l− 1) 2.5 (±2.6) 9.2 (±9.8) 436.5 o0.001
Selected haematology markers
Haemoglobin (g l− 1) 143.9 (±7.5) 136.9 (±12.1) 3.15 0.002
Haematocrit (l l− 1) 0.4 (±0.02) 0.4 (±0.04) 2.43 0.018
Red blood cells (1012 per l) 4.8 (±0.3) 4.6 (±0.4) − 3.37 0.001
White blood cells (109 per l) 5.9 (±1.3) 7.4 (±2.6) 1.73 0.088
Eosinophils (%) 1.8 (±1.1) 3.3 (±1.7) − 4.73 o0.001
Lymphocytes (%) 28.3 (±6.4) 33.7 (±10.2) − 2.92 0.005
Monocytes (%) 7.50 (±1.8) 8.6 (±2.5) − 2.31 0.024
Neutrophils (%) 61.8 (±7.0) 53.7 (±11.7) 3.82 o0.001
Basophils (%) 0.6 (±0.3) 0.7 (±0.4) − 0.90 0.369
Mean cell volume (Fl) 89.4 (±4.6) 88.8 (±6.4) 0.52 0.602
Mean cell haemoglobin (Pg) 30.3 (±1.7) 29.7 (±2.4) 1.18 0.242
Mean corpuscular haemoglobin concentration 338.5 (±6.9) 334.63 (±8.3) 2.27 0.026
Other biomarkers
Creatinine (μmol l− 1) 79.9 (±14.4) 79.7 (±16.1) 0.04 0.970
Total bilirubin (μmol l− 1) 14.2 (±9.8) 6.5 (±3.3) 302.5 o0.001
Conjugated bilirubin (μmol l−1) 3.9 (±2.5) 2.5 (±1.3) 555.5 0.003
Abbreviations: Std., standard deviation. Means and standard deviations appear in parentheses.
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